A phase II trial of preoperative capecitabine plus irinotecan followed by combined modality capecitabine and radiation for locally advanced rectal cancer: Hoosier Oncology Group GI03-53

Trial Profile

A phase II trial of preoperative capecitabine plus irinotecan followed by combined modality capecitabine and radiation for locally advanced rectal cancer: Hoosier Oncology Group GI03-53

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2011 Planned end date changed from 1 Jun 2009 to 1 May 2008 as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Planned end date changed from 1 Dec 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top